| 16.72 0.05 (0.3%) | 03-30 15:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.69 | 1-year : | 21.44 |
| Resists | First : | 17.72 | Second : | 18.36 |
| Pivot price | 17.1 |
|||
| Supports | First : | 16.68 | Second : | 13.88 |
| MAs | MA(5) : | 16.92 |
MA(20) : | 17.26 |
| MA(100) : | 17.19  |
MA(250) : | 15 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 24.5 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 18.87 | Low : | 10.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ WDNA ] has closed above bottom band by 19.3%. Bollinger Bands are 6.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.92 - 17.02 | 17.02 - 17.11 |
| Low: | 16.47 - 16.59 | 16.59 - 16.71 |
| Close: | 16.54 - 16.72 | 16.72 - 16.89 |
The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
Fri, 27 Mar 2026
Stock List: Research Stocks from Around the World - gurufocus.com
Wed, 25 Mar 2026
Discipline and Rules-Based Execution in WDNA Response - Stock Traders Daily
Mon, 16 Feb 2026
Top ETFs Tracking CRISPR Gene Editing for 2026 - fool.com
Thu, 02 Oct 2025
Investing in Biotech ETFs - FOREX.com
Tue, 22 Jul 2025
Beyond The Buzz - Segmenting AI Exposure - Seeking Alpha
Tue, 17 Jun 2025
Investing in Biotech ETFs - FOREX.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
CBOE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|